Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1)

Analgesic (2) · GABAergic (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Antifungals|Antifungal]] (1) · [[:Category:Hydroxypyridones|Hydroxypyridone]] (1) · [[:Category:Topical_antifungals|Topical antifungal]] (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of GHB (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00001235-QINU`"', '"`UNIQ--vote-00001236-QINU`"', '"`UNIQ--vote-00001237-QINU`"', '"`UNIQ--vote-00001238-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1)

None (2) · 0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · BID topical; once daily nail lacquer (1)

None (2) · PO (only formulation marketed in the US). (1) · Topical (1)

None (2) · 30–60 min (PO) (1) · Days for dermatophyte clearance; nail clearance over months (1)

None (2) · 4–6 hours (1) · Hours per application (1)

None (2) · 2.5–3 hours (1) · Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1)

None (2) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)